ECSP055914A - Combinación farmacéutica para la prevención o la terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales - Google Patents
Combinación farmacéutica para la prevención o la terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renalesInfo
- Publication number
- ECSP055914A ECSP055914A EC2005005914A ECSP055914A ECSP055914A EC SP055914 A ECSP055914 A EC SP055914A EC 2005005914 A EC2005005914 A EC 2005005914A EC SP055914 A ECSP055914 A EC SP055914A EC SP055914 A ECSP055914 A EC SP055914A
- Authority
- EC
- Ecuador
- Prior art keywords
- prevention
- therapy
- cardiopulmonary
- pulmonary
- cardiovascular
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 4
- 238000002560 therapeutic procedure Methods 0.000 title abstract 3
- 230000002612 cardiopulmonary effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 2
- 230000002685 pulmonary effect Effects 0.000 title abstract 2
- RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 abstract 4
- 239000005537 C09CA07 - Telmisartan Substances 0.000 abstract 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 abstract 2
- 208000001280 Prediabetic State Diseases 0.000 abstract 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 201000009104 prediabetes syndrome Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 abstract 2
- 229960002855 simvastatin Drugs 0.000 abstract 2
- 229960005187 telmisartan Drugs 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000006306 Cor pulmonale Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000036772 blood pressure Effects 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000008753 endothelial function Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000029865 regulation of blood pressure Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un procedimiento para la prevención o la terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales mediante la mejora de la función endotelial y la obtención de una protección de los órganos, los tejidos y los vasos sanguíneos en indicaciones en las que es necesario un control de la tensión arterial y de los niveles de lípidos, particularmente en personas a las que se ha diagnosticado diabetes mellitus de tipo 2 o en las que existe la sospecha de prediabetes, para la prevención de la diabetes y la prediabetes o para el tratamiento del síndrome metabólico y la resistencia a insulina en pacientes con tensión arterial normal. El procedimiento comprende la administración conjunta de cantidades eficaces de telmisartan o de un polimorfo o una sal del mismo y simvastatina. La invención también se refiere a composiciones farmacéuticas adecuadas que contienen telmisartan o un polimorfo o una sal del mismo y simvastatina, en forma de una preparación combinada para uso simultáneo, separado o secuencial en la prevención o la terapia de estas enfermedades.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10301372A DE10301372A1 (de) | 2003-01-16 | 2003-01-16 | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| DE10335027A DE10335027A1 (de) | 2003-07-31 | 2003-07-31 | Verwendung von Angiotensin II Rezeptor Antagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP055914A true ECSP055914A (es) | 2006-03-01 |
Family
ID=32714792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2005005914A ECSP055914A (es) | 2003-01-16 | 2005-07-12 | Combinación farmacéutica para la prevención o la terapia de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20050004193A1 (es) |
| EP (2) | EP1818056A1 (es) |
| JP (1) | JP2006515877A (es) |
| KR (1) | KR20050092119A (es) |
| AT (1) | ATE362782T1 (es) |
| AU (1) | AU2004204353A1 (es) |
| BR (1) | BRPI0406812A (es) |
| CA (1) | CA2513281C (es) |
| CY (1) | CY1106775T1 (es) |
| DE (1) | DE502004003880D1 (es) |
| DK (1) | DK1587584T3 (es) |
| EA (1) | EA009886B1 (es) |
| EC (1) | ECSP055914A (es) |
| ES (1) | ES2287689T3 (es) |
| HR (1) | HRP20050655A2 (es) |
| MX (1) | MXPA05007559A (es) |
| NO (1) | NO20053793L (es) |
| PL (1) | PL376213A1 (es) |
| PT (1) | PT1587584E (es) |
| RS (1) | RS20050536A (es) |
| SI (1) | SI1587584T1 (es) |
| WO (1) | WO2004062729A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
| PL1814527T5 (pl) * | 2004-11-05 | 2021-08-02 | Boehringer Ingelheim International Gmbh | Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę |
| WO2007051007A2 (en) * | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
| US20090030057A1 (en) * | 2005-11-22 | 2009-01-29 | Shlomit Wizel | Pharmaceutical composition of telmisartan |
| JP5558104B2 (ja) * | 2006-12-11 | 2014-07-23 | スリー−ディー マトリックス， インコーポレイテッド | 心組織の保護および再生のための組成物および方法 |
| KR101209319B1 (ko) | 2008-04-29 | 2012-12-06 | 한올바이오파마주식회사 | 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 |
| WO2010075347A2 (en) * | 2008-12-23 | 2010-07-01 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone |
| EP2787993B1 (en) * | 2011-12-09 | 2016-11-23 | Artskin D.O.O. | TREATMENT OF ARTERIAL WALL BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR |
| WO2013136277A1 (en) * | 2012-03-13 | 2013-09-19 | Unimark Remedies Ltd. | Pharmaceutical compositions for treatment of cardiovascular diseases |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ330774A (en) * | 1996-04-05 | 1999-06-29 | Takeda Chemical Industries Ltd | Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity |
| US20010006656A1 (en) * | 1999-02-17 | 2001-07-05 | University Of Washington | Methods and compositions for inhibiting inflammation associated with pulmonary disease |
| DK1216038T3 (da) * | 1999-08-30 | 2005-12-27 | Sanofi Aventis Deutschland | Anvendelse af inhibitorer af reninangiotensinsystemet ved forebyggelsen af cardiovaskulære hændelser |
| US20040023840A1 (en) * | 2000-04-12 | 2004-02-05 | Marc De Gasparo | Combination of organic compounds |
| US20020013334A1 (en) * | 2000-06-15 | 2002-01-31 | Robl Jeffrey A. | HMG-CoA reductase inhibitors and method |
| EP1314425A4 (en) * | 2000-08-30 | 2004-06-02 | Sankyo Co | MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| JP4585198B2 (ja) * | 2002-12-27 | 2010-11-24 | 武田薬品工業株式会社 | 体重増加抑制剤 |
-
2004
- 2004-01-14 EP EP07105299A patent/EP1818056A1/de not_active Withdrawn
- 2004-01-14 WO PCT/EP2004/000175 patent/WO2004062729A1/de not_active Ceased
- 2004-01-14 MX MXPA05007559A patent/MXPA05007559A/es active IP Right Grant
- 2004-01-14 AT AT04701918T patent/ATE362782T1/de active
- 2004-01-14 BR BR0406812-2A patent/BRPI0406812A/pt not_active IP Right Cessation
- 2004-01-14 ES ES04701918T patent/ES2287689T3/es not_active Expired - Lifetime
- 2004-01-14 EA EA200501057A patent/EA009886B1/ru not_active IP Right Cessation
- 2004-01-14 RS YUP-2005/0536A patent/RS20050536A/sr unknown
- 2004-01-14 KR KR1020057013209A patent/KR20050092119A/ko not_active Withdrawn
- 2004-01-14 DE DE502004003880T patent/DE502004003880D1/de not_active Expired - Lifetime
- 2004-01-14 EP EP04701918A patent/EP1587584B1/de not_active Expired - Lifetime
- 2004-01-14 JP JP2006500558A patent/JP2006515877A/ja active Pending
- 2004-01-14 DK DK04701918T patent/DK1587584T3/da active
- 2004-01-14 PL PL04376213A patent/PL376213A1/xx not_active Application Discontinuation
- 2004-01-14 CA CA2513281A patent/CA2513281C/en not_active Expired - Fee Related
- 2004-01-14 AU AU2004204353A patent/AU2004204353A1/en not_active Abandoned
- 2004-01-14 HR HR20050655A patent/HRP20050655A2/xx not_active Application Discontinuation
- 2004-01-14 PT PT04701918T patent/PT1587584E/pt unknown
- 2004-01-14 US US10/757,015 patent/US20050004193A1/en not_active Abandoned
- 2004-01-14 SI SI200430377T patent/SI1587584T1/sl unknown
-
2005
- 2005-07-12 EC EC2005005914A patent/ECSP055914A/es unknown
- 2005-08-10 NO NO20053793A patent/NO20053793L/no not_active Application Discontinuation
-
2007
- 2007-07-30 CY CY20071101012T patent/CY1106775T1/el unknown
-
2011
- 2011-04-13 US US13/086,131 patent/US20110190277A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA05007559A (es) | 2005-09-21 |
| CA2513281C (en) | 2012-04-03 |
| US20110190277A1 (en) | 2011-08-04 |
| RS20050536A (sr) | 2007-09-21 |
| CA2513281A1 (en) | 2004-07-29 |
| SI1587584T1 (sl) | 2007-10-31 |
| HRP20050655A2 (en) | 2006-05-31 |
| EA009886B1 (ru) | 2008-04-28 |
| EP1818056A1 (de) | 2007-08-15 |
| EA200501057A1 (ru) | 2006-02-24 |
| KR20050092119A (ko) | 2005-09-20 |
| US20050004193A1 (en) | 2005-01-06 |
| PT1587584E (pt) | 2007-06-11 |
| EP1587584A1 (de) | 2005-10-26 |
| DE502004003880D1 (de) | 2007-07-05 |
| NO20053793L (no) | 2005-08-10 |
| BRPI0406812A (pt) | 2005-12-27 |
| CY1106775T1 (el) | 2012-05-23 |
| PL376213A1 (en) | 2005-12-27 |
| ES2287689T3 (es) | 2007-12-16 |
| WO2004062729A8 (de) | 2004-10-07 |
| ATE362782T1 (de) | 2007-06-15 |
| EP1587584B1 (de) | 2007-05-23 |
| AU2004204353A1 (en) | 2004-07-29 |
| JP2006515877A (ja) | 2006-06-08 |
| DK1587584T3 (da) | 2007-09-24 |
| WO2004062729A1 (de) | 2004-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jaspan et al. | Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function | |
| NO20073456L (no) | Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling | |
| CY1106775T1 (el) | Φαρμακευτικος συνδυασμος για την προληψη ή θεραπεια καρδιαγγειακων, καρδιοπνευμονικων πνευμονικων ή νεφρικων παθησεων | |
| UA84282C2 (ru) | Применение телмисартана и аторвастатина для лечения сахарного диабета типа іі и фармацевтическая композиция | |
| RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
| Colwell et al. | Propylthiouracil-induced agranulocytosis, toxic hepatitis, and death: Report of a case | |
| JP2014513121A5 (es) | ||
| Appel | Detecting and controlling diabetic nephropathy: what do we know | |
| Tan et al. | Cutaneous larva migrans complicated by Löffler syndrome | |
| Oanta et al. | Half and half nails in a healthy person | |
| KR101758949B1 (ko) | 활성 성분으로 ｌ-카르니틴 또는 프로피오닐 ｌ-카르니틴을 포함하는, 만성 정맥 기능부전의 예방 또는 치료용 복합 조성물 | |
| CN103948620B (zh) | 一种含有山栀苷甲酯的药物组合物及应用 | |
| Liu et al. | P3564 Alogliptin, a DPP-4 inhibitor, alleviates atrial remodeling and improves mitochondrial function and biogenesis in diabetic rabbits | |
| Trikha et al. | A case of myocarditis mimicking myocardial infarction in hair dye poisoning | |
| Shawis et al. | Diabetic black toe is a marker for fatal myocardial infarction | |
| Mihalcea et al. | MEN 2A SYNDROME–A SURPRISING CAUSE FOR SECONDARY HYPERTENSION | |
| Karamat et al. | PP. LB03. 18: TOLERANCE TO ACUTE EFFECT OF THE CREATINE KINASE INHIBITOR BETA-GUANIDINOPROPIONIC ACID (ABC-TRIAL). A RANDOMIZED PLACEBO-CONTROLLED FIRST-IN-MEN TRIAL | |
| Ayres | Tetracycline treatment of telangiectasia | |
| Jun et al. | e0273 Relationship of peripheral arterial disease, chronic kidney disease, and mortality in Chinese hypertensive patients | |
| Zhumadilova et al. | Rehabilitation of patients with chronic liver diseases and its efficiency monitoring in the increased radiation risk region of East Kazakhstan area | |
| Qiang et al. | e0272 Low testosterone levels are inversely associated with carotid artery plaque formation | |
| Lee et al. | LBPS 02-47 CARDIOVASCULAR OUTCOMES ACCORDING TO LDL CHOLESTEROL LEVELS IN EMPA-REG OUTCOME | |
| Lundbæk et al. | Angiopathy? | |
| Eswarappa et al. | Renal cortical necrosis in a renal transplant recipient | |
| Koziolova et al. | PP. 21.02: INFLUENCE OF FIXED COMBINATION OF PERINDOPRIL AND AMLODIPINE IN ARTERIAL HYPERTENSION AND COPD PATIENTS ON CHRONIC HEART FAILURE AND RESPIRATORY FUNCTION |